Abstract：
OBJECTIVE: There are two main subtypes of mucinous carcinoma (MC) based on the quantification of the mucinous component: the pure variant (pMC) and the mixed variant (mMC). pMC has been subdivided into pure A with a hypocellular variant, and pure B with a hypercellular variant.
METHODS: We retrospectively analyzed the clinicopathological features of 99 patients with MC who were treated at our institution from January 2002 to December 2014. We evaluated the expression profiles of markers, including mucin (MUC) family members, in the patients groups representing different MC subtypes by performing immunohistochemistry to identify factors involved in the differentiation and progression of MCs.
RESULTS: Among the 99 patients, 76 (76.8%) had pure mucinous carcinomas (pMC) and the other 23 (23.2%) had mixed mucinous carcinomas (mMC). Of the pMCs, 54 were pure A and 22 were pure B. The prognosis was worse for pure B than pure A and worse for mMC than pMC. Although there was no significant difference in clinicopathological factors between the pure A and pure B groups, immunohistochemical staining revealed differences in the localization of mucin MUC1 and β-catenin. A comparison of the pMC and mMC cases revealed more lymphovascular invasion in mMC and differences in the localization of β-catenin between the two groups.
CONCLUSIONS: The patients\' prognoses were significantly poorer depending on the histologic subtype (in the order pure A, pure B, and mixed). MUC1 localization and β-catenin were revealed as independent predictors contributing to the poorer prognosis.
METHODS: We retrospectively analyzed the clinicopathological features of 99 patients with MC who were treated at our institution from January 2002 to December 2014. We evaluated the expression profiles of markers, including mucin (MUC) family members, in the patients groups representing different MC subtypes by performing immunohistochemistry to identify factors involved in the differentiation and progression of MCs.
RESULTS: Among the 99 patients, 76 (76.8%) had pure mucinous carcinomas (pMC) and the other 23 (23.2%) had mixed mucinous carcinomas (mMC). Of the pMCs, 54 were pure A and 22 were pure B. The prognosis was worse for pure B than pure A and worse for mMC than pMC. Although there was no significant difference in clinicopathological factors between the pure A and pure B groups, immunohistochemical staining revealed differences in the localization of mucin MUC1 and β-catenin. A comparison of the pMC and mMC cases revealed more lymphovascular invasion in mMC and differences in the localization of β-catenin between the two groups.
CONCLUSIONS: The patients\' prognoses were significantly poorer depending on the histologic subtype (in the order pure A, pure B, and mixed). MUC1 localization and β-catenin were revealed as independent predictors contributing to the poorer prognosis.
摘要：
目的：基于粘液性成分的定量，粘液性癌（MC）有两种主要亚型：纯变体（pMC）和混合变体（mMC）。pMC已被细分为具有低细胞变异的纯A，和具有高细胞变异的纯B。
方法：我们回顾性分析了2002年1月至2014年12月在我院接受治疗的99例MC患者的临床病理特征。我们评估了标志物的表达谱，包括粘蛋白（MUC）家族成员，在代表不同MC亚型的患者组中，通过进行免疫组织化学来确定与MC分化和进展有关的因素。
结果：在99名患者中，76例（76.8％）患有纯粘液性癌（pMC），其他23例（23.2％）患有混合粘液性癌（mMC）。在pMC中，54例为纯A，22例为纯B。纯B的预后比纯A差，mMC的预后比pMC差。虽然单纯A组和单纯B组的临床病理因素差异无统计学意义,免疫组织化学染色显示粘蛋白MUC1和β-catenin的定位存在差异。pMC和mMC病例的比较显示mMC中更多的淋巴血管侵犯以及两组之间β-catenin的定位差异。
结论：根据组织学亚型的不同，患者的预后明显较差（按照纯A的顺序，纯B,和混合）。MUC1定位和β-catenin是导致预后较差的独立预测因子。
方法：我们回顾性分析了2002年1月至2014年12月在我院接受治疗的99例MC患者的临床病理特征。我们评估了标志物的表达谱，包括粘蛋白（MUC）家族成员，在代表不同MC亚型的患者组中，通过进行免疫组织化学来确定与MC分化和进展有关的因素。
结果：在99名患者中，76例（76.8％）患有纯粘液性癌（pMC），其他23例（23.2％）患有混合粘液性癌（mMC）。在pMC中，54例为纯A，22例为纯B。纯B的预后比纯A差，mMC的预后比pMC差。虽然单纯A组和单纯B组的临床病理因素差异无统计学意义,免疫组织化学染色显示粘蛋白MUC1和β-catenin的定位存在差异。pMC和mMC病例的比较显示mMC中更多的淋巴血管侵犯以及两组之间β-catenin的定位差异。
结论：根据组织学亚型的不同，患者的预后明显较差（按照纯A的顺序，纯B,和混合）。MUC1定位和β-catenin是导致预后较差的独立预测因子。
